Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

n Therapeutics. "We are also very pleased with the safety profile demonstrated by Contrave thus far. We look forward to the results from the remaining Phase 3 trials which will further examine the efficacy, safety and tolerability of Contrave with less intensive behavior modification as well as in patients with Type 2 diabetes patients."

Patient enrollment has been completed in the three other Phase 3 trials. Orexigen expects to announce top-line results from these trials in mid-2009 and, pending additional positive results, submit a New Drug Application (NDA) with the FDA in late 2009.

Study Details and Results

The objective of this NB-302 trial was to determine the additional weight loss and health benefits of Contrave when added to an intensive diet and exercise program. The trial included the most intensive behavior modification regimen of the Phase 3 program for Contrave, which resulted, as expected, in a high degree of weight loss among placebo patients.

This 56-week, double-blind, placebo-controlled trial conducted at nine U.S. centers evaluated the efficacy and safety of Contrave (32mg naltrexone SR/360mg bupropion SR) compared to placebo in 793 obese patients who participated in an intense behavioral program consisting of counseling, diet and exercise. Patients enrolled in the trial were randomized on a 3 to 1 ratio between Contrave and placebo, and had a body mass index (BMI) of 30 to 45, or as low as 27 in the presence of cardiometabolic co-morbidities. Drug dosages were initially titrated over a four week period and then administered over 52 weeks of therapy at full dose. The co-primary endpoints were percent change in total body weight from baseline and proportion of patients who lost at least 5% of their baseline body weight.

    Efficacy results from this trial are summarized in the following table:

                          Intent-To-Treat*            
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Look inside ... hard-working items for the lab, from fluid handling to ... (GIS)—ready to ship when you order. , Preferred ... Pumps , from the L/S® model for precise flow ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... March 20, 2012 /PRNewswire-iReach/ -- Systems Alliance, ... build, assess and optimize online properties, today announced it ... The Living Legacy Foundation . The non-profit organization facilitates ... for transplantation and research in Maryland with the exception ...
... FULTON, Miss., March 20, 2012  Frank A. Critz, M.D., founder ... honored with a hometown hero,s welcome this April when he ... prostate cancer survivors.  The event will be April 14, 2012 ... Street in Fulton from noon until 3 p.m., and lunch ...
... 2012 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an ... fight Human Immunodeficiency Virus (HIV) infections, announced today ... certain institutional investors, pursuant to which the Company ... A convertible preferred stock at an aggregate purchase ...
Cached Biology Technology:Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland 2Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland 3Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2GeoVax Announces Private Placement of $2.2 Million 2GeoVax Announces Private Placement of $2.2 Million 3GeoVax Announces Private Placement of $2.2 Million 4
(Date:7/9/2014)... some shark species may be able to cope with the ... temperatures. , The Arctic today is best known for its ... that. Roughly 53 to 38 million years ago during what ... similar to a huge temperate forest with brackish water, home ... hippo-like creatures, crocodiles and giant tortoises. Much of what is ...
(Date:7/9/2014)... The U.S. may be on the verge of an economy ... burns cleaner than coal and is undergoing a production boom. ... globally, but recent research is casting serious doubts over just ... Chemical & Engineering News (C&EN), the weekly news magazine ... Johnson, a senior correspondent at C&EN, explains that when burned ...
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
Breaking Biology News(10 mins):Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... -- The Society of Environmental Toxicology and Chemistry will present ... its 33rd Annual Meeting, November 11 at the Long Beach ... the Rosenstiel School of Marine & Atmospheric Science of the ... to the understanding of fate and effects of metals in ...
... Four young scientists have received postdoctoral fellowships from the ... program, they conduct research with the eventual aim of ... receiving mentorship from a faculty member at their home ... seven research teams. This allows them to interact with ...
... 2012  Verinata Health, Inc., a privately-held company dedicated to ... at the 62 nd Annual Meeting of the ... being held in San Francisco, California. (Logo: ... offers pregnant women access to a blood test that ...
Cached Biology News:SETAC announces Chris Lee Award for metals research winner, Kevin Brix 2Space research institute awards postdoctoral fellowships to 4 scientists 2Verinata Health Announces New Findings At The American Society Of Human Genetics 2
... Activins are polypeptide hormones which ... (TGF-) superfamily. The TGF- superfamily is ... factors which control many aspects of ... (1). Other members incude TGF-s, bone ...
... Beads Sterile plating in just seconds ... and potentially hazardous ethanol flaming, More uniform ... ready-to-use sterile packaging: dispenser bottle for spreading 100 ... Fastest and easiest way to spread cells ...
... a regulated environment, Pipette Tracker Pro ... that automates gravimetric pipette calibration and ... meets todays regulatory compliance requirements. Pipette ... that includes a full security implementation, ...
... (RTL) can provide you with the ... method development and validation ,Performance of ... of your GMP manufacturing environment ,Assurance ... a full spectrum of microbiological services ...
Biology Products: